Clinical trials: sponsored by Incyte Corporation
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
- Trial name
- TRuE-PN2 (NCT05764161)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 76 sites in United States, Australia and 11 more
- Volunteers
- 190 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week…
- Trial name
- STOP-HS2 (NCT05620836)
- Testing
- Povorcitinib
- Where
- 101 sites in United States, Australia and 9 more
- Volunteers
- 619 people
- Sponsor
- Incyte Corporation
Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
This is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with…
- Trial name
- J-MIND (NCT04661007)
- Testing
- tafasitamab, lenalidomide, parsaclisib
- Where
- 23 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Incyte Biosciences Japan GK
Atopic Dermatitis
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and…
- Trial name
- TRuE-AD4 (NCT06238817)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 241 people
- Sponsor
- Incyte Corporation
Chronic Graft-versus-host-disease
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
This study will be conducted to determine the clinical efficacy of axatilimab in Japanese participants with chronic graft-versus-host disease (cGVHD).
- Trial name
- NCT06263478
- Testing
- INCA034176
- Where
- 16 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Incyte Biosciences Japan GK
Anemia, Post-essential Thrombocythemia Myelofibrosis
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are…
- Conditions
- Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
- Trial name
- NCT04455841
- Testing
- INCB000928, ruxolitinib
- Where
- 34 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Incyte Corporation
Head and Neck Cancer
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line…
- Trial name
- NCT03358472
- Testing
- Pembrolizumab, Epacadostat, Cetuximab
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 89 people
- Sponsor
- Incyte Corporation
Squamous Cell Carcinoma of the Anal Canal
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
- Trial name
- NCT04472429
- Testing
- carboplatin, paclitaxel, retifanlimab
- Where
- 84 sites in United States, Australia and 11 more
- Volunteers
- 308 people
- Sponsor
- Incyte Corporation
Head and Neck Cancer
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in…
- Trial name
- NCT05287113
- Testing
- Retifanlimab, INCAGN02385, INCAGN02390
- Where
- 91 sites in United States, Belgium and 12 more
- Volunteers
- 176 people
- Sponsor
- Incyte Biosciences International Sàrl
Advanced Solid Tumors
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.
- Trial name
- NCT06039384
- Testing
- INCB099280, adagrasib
- Where
- 14 sites in United States, Italy and 2 more
- Volunteers
- 6 people
- Sponsor
- Incyte Corporation
Follicular Lymphoma, Marginal Zone Lymphoma
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an…
- Trial name
- InMIND (NCT04680052)
- Testing
- tafasitamab, rituximab, lenalidomide
- Where
- 261 sites in United States, Australia and 26 more
- Volunteers
- 654 people
- Sponsor
- Incyte Corporation
Melanoma
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
- Trial name
- NCT04370704
- Testing
- INCAGN02385, INCAGN02390, INCMGA00012.
- Where
- 17 sites in United States, Australia
- Volunteers
- 61 people
- Sponsor
- Incyte Corporation
Prurigo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
- Trial name
- TRuE-PN1 (NCT05755438)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 71 sites in United States, Argentina and 9 more
- Volunteers
- 204 people
- Sponsor
- Incyte Corporation
Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2…
- Trial name
- FIGHT-302 (NCT03656536)
- Testing
- Pemigatinib, Gemcitabine, Cisplatin
- Where
- 215 sites in United States, Austria and 17 more
- Volunteers
- 167 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.
- Trial name
- BREEZE-AD-PEDS (NCT03952559)
- Testing
- Baricitinib, Topical corticosteroid
- Where
- 78 sites in Argentina, Australia and 15 more
- Volunteers
- 516 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study of Baricitinib in Participants With Rheumatoid Arthritis
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis…
- Trial name
- RA-BRANCH (NCT04086745)
- Testing
- Baricitinib, TNF Inhibitor
- Where
- 119 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- Eli Lilly and Company
Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
- Trial name
- POD1UM-304 (NCT04205812)
- Testing
- Retifanlimab, Pemetrexed, Cisplatin
- Where
- 140 sites in United States, Brazil and 15 more
- Volunteers
- 583 people
- Sponsor
- Incyte Corporation
Rheumatoid Arthritis
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
- Trial name
- RA-BRIDGE (NCT03915964)
- Testing
- Baricitinib, TNF Inhibitor
- Where
- 261 sites in United States, Australia and 22 more
- Volunteers
- 2,659 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib.
- Trial name
- NCT05949632
- Testing
- INCB099280, axitinib
- Where
- 6 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Renal Cell Carcinoma (RCC)
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell…
- Trial name
- NCT03260894
- Testing
- Pembrolizumab, Epacadostat, Sunitinib
- Where
- 140 sites in United States, Australia and 18 more
- Volunteers
- 129 people
- Sponsor
- Incyte Corporation